Alzheimer's disease is identified by the deposition of amyloid β-proteins extracellularly and phosphorylated tau proteins intracellularly in the grey matter of the brain. The formation of amyloid plaques leads to the inflammatory response in the region of the entorhinal cortex, hippocampus, and cerebral cortex. Agonisticaction on PPAR-γ has been reported to possess anti-inflammatory and neuroprotective functions. Glitazone is a versatile molecule with PPAR-γ agonistic activity which leads to neuroprotective and anti-inflammatory actions. Biological activities and the low cost of glitazone attracted scientists to explore novel clinical uses of the drug. This led to different clinical investigations of glitazones in animals and humans in the last decade. In this review, authors presented glitazones ongoing development and potency as neuroprotective and anti-inflammatory agents in Alzheimer disease with reported mechanisms. The review will help develop new clinical investigations of glitazones as Anti-alzheimer and other cognitive and neurodegenerative disorders.